(NASDAQ: EXEL) Exelixis's forecast annual revenue growth rate of 9.53% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Exelixis's revenue in 2025 is $2,298,922,000.On average, 10 Wall Street analysts forecast EXEL's revenue for 2025 to be $635,023,592,059, with the lowest EXEL revenue forecast at $619,047,795,600, and the highest EXEL revenue forecast at $671,263,249,972. On average, 10 Wall Street analysts forecast EXEL's revenue for 2026 to be $713,866,555,598, with the lowest EXEL revenue forecast at $678,225,492,360, and the highest EXEL revenue forecast at $777,024,975,121.
In 2027, EXEL is forecast to generate $830,707,872,747 in revenue, with the lowest revenue forecast at $723,767,775,120 and the highest revenue forecast at $941,980,759,528.